[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"calcium-pyrophosphate-deposition-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:calcium-pyrophosphate-deposition-disease":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,41,73],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100612519","phase-2-tocilizumab-in-chronic-inflammatory-cppd-disease-100612519",false,"NCT07254637","Tocilizumab in Chronic Inflammatory CPPD Disease","Randomized, Double-blind, Multicentre Trial of Tocilizumab Versus Placebo in Chronic Polyarticular Inflammatory of Calcium Pyrophosphate Deposition Disease Refractory to Standard Treatments","TociCCAre","Inclusion Criteria:\n\n* Adults \\> 18 years\n* Diagnosis of CPPD according to ACR\u002FEULAR 2023 classification criteria\n* Persistent inflammatory pain (\\> 3 months) or ≥ 2 arthritics\u002Fmonth\n* Number of painful joints (NAD) \\> 3\n* Overall pain VAS (0\\_100) \\> 40 mm\n* Failure, intolerance or impossibility of repeated use of usual treatments: colchicine, NSAIDs, corticosteroids and anakinra\n* Use of an effective method of contraception in women of childbearing age until 3 months after the end of the study.\n* Informed consent\n\nExclusion Criteria:\n\n* Presence of anti-CPP antibodies \\> 50 IU\u002Fml\n* Recurrent or chronic infections\n* History of severe infection (= requiring hospitalization)\n* Active infection\n* Vaccination with live or attenuated vaccine within 4 weeks prior to inclusion\n* History of intestinal ulceration or diverticulitis Untreated latent tuberculosis\n* History of viral hepatitis B ou C\n* Symptoms suggestive of demyelinating disease of the central nervous system\n* History of cancer, active cancer, or suspected cancer\n* Neutropenia \\\u003C 2000 elements\u002Fmm3, thrombocytopenia \\\u003C 100 000\u002Fmm3\n* Elevated transaminases \\> 3 x ULN\n* Known hypersensitivity to the active substance or one of the excipients;\n* Known severe immune deficiency\n* Patients not meeting classification criteria\n* Concomitant treatment with biological or targeted therapies, or immunosuppressive therapy (including methotrexate, leflunomide, azathioprine), systemic corticosteroids, anakinra, IL-6 inhibitors in subcutaneous injection, anti-TNF agents, and JAK. If these treatments are used before inclusion, a washout period corresponding to at least five times their respective mean terminal half-life must be respected.\n* inhibitors.\n* Previous treatment with tocilizumab\n* Concomitant treatment with methylprednisolone, dexamethasone, atorvastatin, calcium channel blockers, theophylline, warfarin, phenprocoumon, phenytoin, cyclosporine or benzodiazepines\n* Dyslipidemia, hypertension or poorly controlled cardiovascular disease\n* Scheduled surgery\n* Difficulty to understand French, illiteracy\n* Pregnant women, women in labor or nursing mothers\n* Persons deprived of their liberty, adults under legal protection or unable to express their consent\n* Persons not affiliated to a social security scheme or beneficiaries of such a scheme\n* Participation in another interventional study","ALL","18 Years",{"count":20,"type":21},80,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","The aim of this clinical trial is to determine the efficacy of tocilizumab (an IL-6 inhibitor) in treatment-refractory chronic inflammatory forms of CPPD.\n\nThe main questions this trial aims to answer are:\n\n* Can tocilizumab improve joint pain in patients with chronic inflammatory CPPD disease?\n* Does tocilizumab improve quality of life in patients with chronic inflammatory CPPD disease?\n\nParticipants will receive a monthly infusion of tocilizumab or placebo for three months.",[27],"Calcium Pyrophosphate Deposition Disease","NOT_YET_RECRUITING","2026-01-13",{"date":31,"type":32},"2026-01-14","ACTUAL",{"date":34,"type":21},"2026-04",{"date":36,"type":21},"2029-11",{"name":38,"class":39},"Assistance Publique - Hôpitaux de Paris","OTHER",12,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":17,"minAge":49,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":54,"conditions":55,"keywords":57,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":72},"100593389","calcium-pyrophosphate-deposition-cppd-disease-100593389","NCT07005804","Calcium Pyrophosphate Deposition (CPPD) Disease","Calcium Pyrophosphate Deposition (CPPD) Disease : Clinical and Paraclinical Profile, Gene Expression and Metabolomics of the Acute and Chronic Clinical Phenotype","PYC-OMIC","Inclusion Criteria - Acute forms of CPPD: retrospective part of the study\n\n* Cases included in the COLCHICORT cohort (NCT03128905), for whom this was the first acute episode of CPPD\n\nInclusion Criteria - Chronical forms of CPPD : prospective part of the study\n\n* Patients affiliated to the French social security system\n* Age ≥ 65 years\n* Diagnosis of chronic CPPD (recurrent acute or persistent arthritis), meeting ACR\u002FEULAR 2023,11 classification criteria after evaluation by a rheumatologist in the rheumatology department\n* Progression of CPPD rheumatism for at least 3 months and still active CPPD rheumatism, defined by a visual analogue scale (VAS) of disease activity ≥ 40 and\u002For presentation of at least 1 crisis over the last 3 months\n* Glomerular Filtration Rate (GFR) in Chronic Kidney Disease Epidemiology (CKD EPI Collaboration) ≥ 30ml\u002Fmin\u002F1.73m2\n* Minimum time between the last intake of a crisis treatment and inclusion in the study, depending on their half-life, in order to not interfere with the results of the omics analyses: 2 weeks (Nonsteroidal Anti-Inflammatory Drugs Per Os (PO) or Intramuscular (IM) or Intravenous (IV); corticosteroids PO or IV; colchicine PO; anakinra Subcutaneous (SC), 1 month (methotrexate PO, tocilizumab SC), 3 months (canakinumab SC, tocilizumab IV)\n* Signed written consent for study participation\n\nExclusion Criteria - Acute forms of CPPD:\n\n* Missing data concerning transcriptomic and metabolomic analyses.\n* Opposition\n\nExclusion Criteria - For chronic forms of CPPD:\n\n* History of gout or presence of monosodium urate (MSU) crystals on joint fluid,\n* Cognitive decline (confusion and neurodegenerative diseases)\n* Inability to provide informed consent and disease VAS\n* Patient under guardianship or curatorship","65 Years",{"count":51,"type":21},137,[53],"NA","The goal of this clinical trial is to describe the transcriptomic and metabolomic profile of patients with chronic Calcium Pyrophosphate Deposition (CPPD) compared to those with acute CPPD.\n\nThe hypotheses are as follows :\n\n* It is hypothesised that there is a transcriptomic and metabolomic signature of CPPD which explains why therapeutic responses to different anti-inflammatory treatments differ from one phenotype to another one\n* It is hypothesised that the acute and chronic clinical phenotypes of CPPD have different clinical, biological and imaging characteristics, as well as a differing predisposition toward crystalline deposition and inflammatory pathway activation.\n\nThe management of participants with chronic forms of the disease included in this research was modelled on the usual recommended management, including a biological workup, joint puncture, ultrasound and radiographic workup. Double-energy CT scans and transcriptomic and metabolomic analyses on plasma are not routine tests.",[27,56],"Rheumatic Diseases",[58,59,60,61,62],"Calcium pyrophosphate deposition disease","gene expression","acute clinical phenotype","chronic clinical phenotype","metabolic expression","2025-05-26",{"date":65,"type":32},"2025-06-05",{"date":67,"type":21},"2025-10",{"date":69,"type":21},"2027-11",{"name":71,"class":39},"Lille Catholic University",1,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":17,"minAge":81,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":22,"phases":84,"briefSummary":85,"conditions":86,"keywords":88,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":72},"100575131","phase-2-baricitinib-in-cppd---the-baptist-study-100575131","NCT06768294","Baricitinib in CPPD - the BAPTIST Study","Baricitinib in Calcium PyrophosphAte DePosiTion DIseaSe Trial - a Proof of Concept Phase II Clinical Trial","BAPTIST","Inclusion Criteria:\n\n* Signed Informed Consent;\n* Male and female patients aged ≥55 years;\n* Patients that according to the investigator's judgement will benefit from the proposed treatments (favourable benefit\u002Frisk profile)\n* Menopause for women;(no menses for 12 months without an alternative medical cause. A high follicle stimulating hormone level in the postmenopausal range may be used to confirm a postmenopausal state in women not using hormonal contraception or hormonal replacement therapy. However in the absence of 12 months of amenorrhea, a high follicle stimulating single measurement is insufficient.);\n* Male patients must avoid having a child during the trial and must use one of the highly effective methods of contraception or sexual abstinence or have a menopause partner (no menses for 12 months without an alternative medical cause. A high follicle stimulating hormone level in the postmenopausal range may be used to confirm a postmenopausal state in women not using hormonal contraception or hormonal replacement therapy. However in the absence of 12 months of amenorrhea, a high follicle stimulating single measurement is insufficient). Contraception methods include:\n\n  * Total abstinence (when this is in line with the preferred and usual lifestyle of the subject). Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception\n  * Sterilization of the female partner (have had surgical bilateral oophorectomy with or without hysterectomy), total hysterectomy or tubal ligation at least six weeks before the partner enrollment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow-up hormone level assessment\n  * Male sterilization (vasectomy) at least 6 months prior to screening\n  * Barrier methods of contraception: Condom or Occlusive cap (diaphragm or cervical\u002Fvault caps).\n  * The female partner use oral, (estrogen and progesterone), injected or implanted hormonal methods of contraception or other forms of hormonal contraception that have comparable efficacy (failure rate \\<1%), for example hormone vaginal ring or transdermal hormone contraception or placement of an intrauterine device (IUD) or intrauterine system (IUS)\n* Patients fulfilling the 2023 ACR\u002FEULAR classification criteria for CPPD disease;\n* Patients with feasibility of synovial biopsy at the knee or wrist joint;\n* Patients with CPPD clinical presentation that may be:\n\n  * Subset 1: patients with prevalent polyarticular involvement of the small joints and tendons of hands and wrists (rheumatoid-like subset). Patients that present with prevalent inflammatory involvement of the hands and wrists (joints and\u002For tendons), with or without acute attacks of arthritis of the large joints, will be included in this group. Inclusion criteria will be joint effusion and\u002For synovitis of the II and\u002For III metacarpal phalangeal (MCP) joint of at least one hand, tenosynovitis of at least 1 tendon of one hand or wrist, hyperostosis of the II and\u002For III MCP head;\n  * Subset 2: patients with prevalent involvement of the large joints (oligoarthritis). Patients with recurrent\u002Fpersistent effusion in one or more large joints (independently of the presence and grade of OA), not responsive to a single injection of steroid and white cell count in joint synovial fluid that is more than 2000 cells\u002Fmm3 and\u002For patients with acute monoarticular arthritis, with more than 3 attacks in one joint in the last 12 months, will be included in this group.\n\nExclusion Criteria:\n\n* Patients positive at anticitrullinated positive antibodies (ACPA), any titre;\n\n  * Patients affected by seronegative arthritis or other conditions that may be responsible of arthritis (i.e. gout, rheumatic polymyalgia, etc);\n  * Patients that refuse synovial biopsy or present contraindications, according to investigator's judgement, including (but not limited to) increased risk for bleeding (platelet count \\<100000 or use of anticoagulants), allergy to local anesthetics, suspicion of septic arthritis;\n  * Patients with history of malignancy or lymphoproliferative disease; or have signs or symptoms suggestive of possible lymphoproliferative disease, including lymphadenopathy or splenomegaly; or have active primary or recurrent malignant disease; or have been in remission from clinically significant malignancy for \\< 5 years;\n  * Patients with cervical carcinoma in situ, basal cell carcinoma or squamous cell carcinomas who have had active disease within 3 years of screening for this study;\n  * Patients with active, untreated, acute or chronic infection (such as untreated tuberculosis), or immunocompromised to an extent that such that participation in the study would pose an unacceptable risk to the subject. Patients with treated infections such as latent tuberculosis after completion of the appropriate therapy are not excluded;\n  * Patients with clinically serious infection or that have received intravenous antibiotics for an infection, within 4 weeks of randomization;\n  * Patients with active viral infection that, based on the investigator\\'s clinical assessment, makes the patient an unsuitable candidate for the study;\n  * Patients with serology suggestive for active or chronic hepatitis B or hepatitis C infection; anti-HCV, anti-HBs, anti-HBc antibodies and HBcAg, HBsAg will be tested. Patients that will result positive for anti-HCV and\u002For HBcAg and\u002For HBsAg and\u002For anti-HBc antibodies will be excluded from the study. Patients who are positive for both anti-HBc and antiHBs, but negative for HBcAg and HBsAb could be enrolled.\n  * Patients with symptomatic herpes zoster infection within 12 weeks of screening or recurrent or disseminated (even a single episode) herpes zoster;\n  * Patients with a history of disseminated opportunistic infections (e.g., listeriosis and histoplasmosis);\n  * Patients with a history of venous thromboembolism (VTE), or are considered at high risk for VTE as deemed by the investigator\n  * Patients who are currently on immunosuppressive therapies or have not discontinued them for at least 4 weeks;\n  * Patients with clinically significant (per investigator\\'s judgement) drug or alcohol abuse within the last 6 months preceding the baseline visit;\n  * Patients with any major surgery within 8 weeks prior to baseline or requiring major surgery during the study, which in the opinion of the investigator would pose an unacceptable risk to the patient;\n  * Patients with recent (within past 6 months) cerebrovascular accident, myocardial infarction, coronary stenting and uncontrolled hypertension (confirmed systolic blood pressure \\>160 mmHg or diastolic blood pressure \\>100 mm Hg); patients with less recent major cardiovascular events (\\> 6 months) will be thoroughly assessed for cardiovascular risk taking under consideration all possible risk factors and the disease phenotype and activity and will be included only in case of favourable benefit\u002Frisk ratio according to the principal investigators judgement.\n  * Patients with presence of significant uncontrolled respiratory, hepatic, renal, endocrine, hematologic, neurologic, or neuropsychiatric disorders, or abnormal laboratory screening values that, in the opinion of the investigator, pose an unacceptable risk to the patient if participating in the study or of interfering with the interpretation of the data;\n  * Patients with clinical laboratory test results at screening that are outside the normal reference range of the population and are considered clinically significant, or have any of the following specific abnormalities: neutrophil count \\<1500 cells\u002FµL, lymphocyte count \\<500 cells\u002FµL, platelet count \\<100,000 cells\u002FµL, aspartate transaminase (AST) or alanine aminotransferase (ALT) \\> 2 times the upper limit of normal, haemoglobin \\<10 g\u002FdL for male and female subjects, eGFR \\< 30 mL\u002Fmin;\n  * Patients with any other condition that precludes him\u002Fher from following and completing the protocol, in the opinion of the investigator;\n  * Patients currently enrolled in or discontinued from a clinical trial involving an investigational product or non-approved use of a drug or device within the last 4 weeks or a period of at least 5 half-lives of the last administration of the drug, whichever is longer, or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study.\n  * Hypersensitivity to the active substance or to any of the excipients","55 Years",{"count":83,"type":21},32,[24],"The aim of this clinical trial is to determine if baricitinib is effective in treating calcium pyrophosphate deposition disease (CPPD) in adults. The primary objective is to assess its impact on joint inflammation. The key questions the study seeks to answer are:\n\n* Can baricitinib reduce inflammation in affected joints?\n* Will baricitinib lead to changes in ultrasound findings, such as calcium crystal deposition and synovitis?\n\nResearchers will compare baricitinib to other treatments, including methylprednisolone, colchicine, hydroxychloroquine, and methotrexate with folic acid, for managing CPPD.",[27,87],"Chondrocalcinosis",[89,90,91,92,93,94,95,96],"calcium pyrophosphate deposition disease","chondrocalcinosis","pseudogout","ultrasound","baricitinib","olumiant","synovial biopsy","arthritis","2025-01-06",{"date":99,"type":32},"2025-01-10",{"date":101,"type":21},"2025-01",{"date":103,"type":21},"2027-01",{"name":105,"class":39},"I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio"]